Abstract: OBJECTIVE To systematically evaluate inflammatory responses and pulmonary function in patients with chronic obstructive pulmonary disease(COPD) using different statins. METHODS Collecting studies of COPD patients using statins for more than three months by searching PubMed, Web of Science, Elsevier and CNKI database. RESULTS The results of meta-analysis showed that long-term using statins reduced the levels of inflammatory factors including C-reactive protein(CRP), interleukin-6(IL-6), etc, the SMD(95%CI) were -1.04(-1.38, -0.71) and -0.70(-1.04, -0.36), respectively. Subgroup analysis showed that atorvastatin was more effective in reducing CRP and IL-6, the SMD(95%CI) were -1.61(-2.35, -0.86) and -0.98(-1.29, -0.66), respectively. Long-term using statins increased pulmonary function including lung function index of forced expiratory volume in one second percent(FEV1%) and forced expiratory volume in one second/forced vital capacity(FEV1/FVC%), the SMD(95%CI) were 0.52(0.19, 0.86) and 0.41(0.16, 0.70), respectively. Atorvastatin was more effective in increasing lung function indicators including FEV1% and FEV1/FVC%, the SMD(95%CI) were 0.82(0.55, 1.08) and 0.82(0.46, 1.18), respectively. CONCLUSION Long-term using statins can effectively reduced the inflammatory response and enhanced lung function in COPD patients. The clinical effect of atorvastatin in patients with COPD is better.